ECSP045301A - Uso de derivado de indolopirrolocarbazol y otro agente anticancerosos en combinacion - Google Patents

Uso de derivado de indolopirrolocarbazol y otro agente anticancerosos en combinacion

Info

Publication number
ECSP045301A
ECSP045301A EC2004005301A ECSP045301A ECSP045301A EC SP045301 A ECSP045301 A EC SP045301A EC 2004005301 A EC2004005301 A EC 2004005301A EC SP045301 A ECSP045301 A EC SP045301A EC SP045301 A ECSP045301 A EC SP045301A
Authority
EC
Ecuador
Prior art keywords
combination
pharmaceutically acceptable
cancer
pharmaceutical preparation
indolopirrolocarbazol
Prior art date
Application number
EC2004005301A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045301A publication Critical patent/ECSP045301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Es una combinación de preparaciones farmacéuticas que se administran en forma simultanea, separada o sucesiva en tratamientos para cánceres; comprende las siguientes dos preparaciones separadas: * una preparación farmacéutica que comprende un vehículo o diluyente farmacéuticamente aceptable, y por lo menos un compuesto representado por la formula general (I) (en donde R1 y R2 representan cada uno independientemente hidrógeno, alquilo inferior, etc.; G representa un grupo pentosa, etc.; y X1 y X2 representan cada uno de ellos hidrógeno o halógeno, etc.;) o una sal farmaceúticamente aceptable del compuesto y * una preparación farmacéutica que comprende un vehículo o diluyente farmacéuticamente aceptable y cualquiera de una agente alquilante anticanceroso, antimetabolito, anticanceroso, antibiótico anticanceroso, agente anticanceroso derivado de plantas y similares (la preparación farmacéutica contiene por lo menos un compuesto representado por la formula (I) anterior o una sal farmacéuticamente aceptable del mismo se puede usar en combinación con dos o más de otros agentes anticancerosos); también se provee un método de tratamiento de cánceres, caracterizado por administrar estas preparaciones farmacéuticas en combinación.
EC2004005301A 2002-03-26 2004-09-17 Uso de derivado de indolopirrolocarbazol y otro agente anticancerosos en combinacion ECSP045301A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002084677 2002-03-26

Publications (1)

Publication Number Publication Date
ECSP045301A true ECSP045301A (es) 2004-11-26

Family

ID=28449220

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005301A ECSP045301A (es) 2002-03-26 2004-09-17 Uso de derivado de indolopirrolocarbazol y otro agente anticancerosos en combinacion

Country Status (25)

Country Link
US (1) US20050171036A1 (es)
EP (1) EP1498127A4 (es)
JP (1) JPWO2003080077A1 (es)
KR (1) KR20040097237A (es)
CN (1) CN100490817C (es)
AP (1) AP2004003120A0 (es)
AU (1) AU2002335472B8 (es)
BR (1) BR0215650A (es)
CA (1) CA2480335A1 (es)
CO (1) CO5611155A2 (es)
EA (1) EA008302B1 (es)
EC (1) ECSP045301A (es)
IL (1) IL164193A0 (es)
IS (1) IS7379A (es)
MA (1) MA27247A1 (es)
MX (1) MXPA04009324A (es)
NO (1) NO20044030L (es)
NZ (1) NZ534914A (es)
OA (1) OA12794A (es)
PL (1) PL370866A1 (es)
RS (1) RS84904A (es)
TN (1) TNSN04185A1 (es)
UA (1) UA80552C2 (es)
WO (1) WO2003080077A1 (es)
ZA (1) ZA200406716B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20014256D0 (no) 2001-09-03 2001-09-03 Bjoern Kristiansen Fremstilling av immunstimulerende forbindelse
KR101064901B1 (ko) * 2003-03-20 2011-09-16 나노캐리어 가부시키가이샤 난수용성 항암제와 신규 블록 공중합체를 포함하는 미셀조제물
PL1792927T3 (pl) 2004-09-22 2013-09-30 Nippon Kayaku Kk Nowy kopolimer blokowy, preparat micelarny i lek przeciwnowotworowy zawierający ten preparat micelarny jako składnik czynny
KR100968818B1 (ko) * 2004-12-03 2010-07-08 현대자동차주식회사 차량용 리어 쇽업쇼버의 보호 커버 구조
US20110182909A1 (en) * 2004-12-23 2011-07-28 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
CN100358482C (zh) * 2005-01-31 2008-01-02 武汉理工大学 多功能医用金属支架及制备方法
CN100431607C (zh) * 2005-02-03 2008-11-12 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
US9072776B2 (en) 2005-06-15 2015-07-07 Glycanova As Anti-cancer combination treatment and kit-of-parts
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
CA2652656A1 (en) * 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
CN100571709C (zh) * 2007-06-01 2009-12-23 中国医学科学院医药生物技术研究所 一种有抗肿瘤协同增效作用的药物组合物
USRE46190E1 (en) 2007-09-28 2016-11-01 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
US20090149417A1 (en) * 2007-10-19 2009-06-11 Valeria Ossovskaya Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors
SG185952A1 (en) 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
EP2082745B1 (en) * 2007-12-28 2012-12-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Cancer therapy with a parvovirus combined with chemotherapy
US8920788B2 (en) * 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
EP2284209B1 (en) 2008-05-08 2016-08-31 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
EP2431403B1 (en) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymer conjugate of bioactive substance having hydroxy group
CN102198150B (zh) * 2010-03-26 2013-11-06 中国医学科学院医药生物技术研究所 双活性成分抗肿瘤药物及其应用
CN103221054A (zh) 2010-11-17 2013-07-24 日本化药株式会社 新的胞苷类代谢拮抗剂的高分子衍生物
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
BR112014005452B1 (pt) 2011-09-11 2021-03-16 Nippon Kayaku Kabushiki Kaisha método de produção de copolímero de bloco
CN117486782A (zh) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 一种n-取代咔唑衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589365A (en) * 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5922860A (en) * 1994-05-09 1999-07-13 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
FR2772763B1 (fr) * 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
JP5409981B2 (ja) * 2000-05-15 2014-02-05 セルジーン コーポレイション 癌治療用の組成物および方法

Also Published As

Publication number Publication date
AU2002335472A1 (en) 2003-10-08
WO2003080077A1 (fr) 2003-10-02
RS84904A (en) 2006-12-15
JPWO2003080077A1 (ja) 2005-07-21
AP2004003120A0 (en) 2004-09-30
IS7379A (is) 2004-07-29
EP1498127A1 (en) 2005-01-19
MA27247A1 (fr) 2005-03-01
NZ534914A (en) 2007-01-26
IL164193A0 (en) 2005-12-18
EA008302B1 (ru) 2007-04-27
EA200401254A1 (ru) 2005-02-24
UA80552C2 (en) 2007-10-10
EP1498127A4 (en) 2008-02-06
PL370866A1 (en) 2005-05-30
AU2002335472B2 (en) 2007-12-13
KR20040097237A (ko) 2004-11-17
TNSN04185A1 (en) 2007-03-12
CA2480335A1 (en) 2003-10-02
CO5611155A2 (es) 2006-02-28
US20050171036A1 (en) 2005-08-04
BR0215650A (pt) 2005-01-04
CN1622814A (zh) 2005-06-01
MXPA04009324A (es) 2005-01-25
ZA200406716B (en) 2006-07-26
NO20044030L (no) 2004-12-16
CN100490817C (zh) 2009-05-27
OA12794A (en) 2006-07-10
AU2002335472B8 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
ECSP045301A (es) Uso de derivado de indolopirrolocarbazol y otro agente anticancerosos en combinacion
JP6827092B2 (ja) ルリコナゾール含有外用医薬組成物
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
HUP0303271A2 (hu) Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
UY28132A1 (es) Derivados de pirrolopirimidina
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
BR0211228A (pt) Composto, composição farmacêutica e seus usos
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
TW200638935A (en) Pyridazine derivatives and their use as therapeutic agents
ECSP045411A (es) Derivados de quinolinona
AR033859A1 (es) Inhibidores de la metaloproteinasa de la matriz
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
PA8542701A1 (es) Composición parenteral reconstituible
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
EA200100568A1 (ru) Фармацевтические композиции в капсулах из гидроксипропилметилцеллюлозы
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
RU2007143434A (ru) 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
BRPI0417933A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple